# Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia

> **NCT03150771** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Aripiprazole

## Key facts

- **NCT ID:** NCT03150771
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-14
- **Primary completion:** 2018-04-18
- **Final completion:** 2018-05-02
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2018-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03150771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03150771, "Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03150771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*